Drug Type Small molecule drug |
Synonyms Imaradenant, AZD 4635, HLT 1071 + [1] |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClFN5 |
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N |
CAS Registry1321514-06-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | KR | - | 29 Jul 2020 |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 29 Aug 2019 | |
metastatic non-small cell lung cancer | Phase 2 | US | 08 May 2018 | |
metastatic non-small cell lung cancer | Phase 2 | KR | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | TW | - | 04 May 2018 |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 17 Jun 2016 | |
Colorectal Cancer | Phase 1 | US | 17 Jun 2016 | |
Attention Deficit Disorder With Hyperactivity | Discovery | GB | 12 Nov 2013 | |
Parkinson Disease | Discovery | GB | 20 Mar 2012 |
Phase 1 | Advanced Malignant Solid Neoplasm adenosine A2A receptor | 10 | sdvgnrcynr(bdclsakifh) = The most common adverse events were nausea, malaise, decreased appetite, and vomiting. zxtmgrpzqk (isjlgxbtsy ) View more | Positive | 01 Apr 2024 | ||
NCT04089553 (Pubmed) Manual | Phase 2 | 59 | wuicyzqcdh(hummrkksca) = qljfinjlby lwgyeyoeba (ahdmgwznwf ) View more | Negative | 02 Mar 2024 | ||
wwpfdzpuie(bzlxapsxlz) = lyvdfcihia rarwcnrzxr (rrygiqvzfh ) View more | |||||||
Phase 2 | 30 | (Arm A: AZD4635 + Durvalumab) | eqowlrlsqo(vagxzbntzj) = gbinnkxndc kjjoocffwv (pzvzzregha, svcguxudpr - gwcwiszhgi) View more | - | 09 Aug 2023 | ||
(Arm B: AZD4635 + Durvalumab + Cabazitaxel) | jnpkvgjkhi(nplzmgkykt) = yzxewxcacv jromthtwhd (efrkhfpros, setoiluabn - ygevhvkmhb) View more | ||||||
Phase 2 | 28 | nwxetdescx(qphzfnhtpc) = gcodbauhqm wgymhhiynq (cljpuhsxno, 4.2–NE) View more | Negative | 21 Feb 2023 | |||
NCT04089553 (ESMO2022) Manual | Phase 2 | 59 | bkfpayvhia(meevllcwud) = pwvnblqyep sluroznfvr (zzgejqhnrw ) View more | Negative | 10 Sep 2022 | ||
bkfpayvhia(meevllcwud) = rzpsjkuzss sluroznfvr (zzgejqhnrw ) View more | |||||||
Phase 2 | 59 | (Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)) | dtmxeiasau(krzalcpmrr) = plagrgrjbk yffrrapefh (sdhbnzvzfk, ktdwlsmdhq - sfikcbltuz) View more | - | 08 Jul 2022 | ||
dtmxeiasau(krzalcpmrr) = dnnsgnexfn yffrrapefh (sdhbnzvzfk, pxqjxfasvp - sduztmgypt) View more | |||||||
Phase 1 | - | wrcphkaivj(wqkeyjinok) = tvqrbrveee hnvlijlgpb (oxlldawldm ) View more | - | 15 Aug 2020 | |||
tzsowdnwsq(tucafeajfi) = trxqccvdlm dgmxltrpzo (qbynrbmyoo ) View more | |||||||
NCT02740985 (ASCO2020) Manual | Phase 1 | 94 | egdfmubqov(wxclpvkzkw) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. ppcjdpjjln (ncglcoihvs ) View more | Positive | 29 May 2020 | ||